R&D News | pharmaphorum

News

Lundbeck names Tarek Samad to replace its retiring R&D chief, Johan Luthman, and he is facing a tough task as the firm heads towards a patent cliff.

News

Ollin has followed its $100m Series A last year with a massive $330m second round that will fund phase 3 trials of its challenger to Roche's Vabysmo.

News

RQ Bio has raised $115m for clinical trials of RQB01, a one-shot antibody designed for strain-agnostic protection against seasonal influenza viruses.

News

The US launches a concerted effort to "restore American leadership in clinical trials" as it deals with the emergence of China as a global R&D hub.

News

One of the antibody-drug conjugates at the heart of Pfizer's $43bn acquisition of Seagen three years ago has failed a phase 3 lung cancer trial.

News

MSD's tulisokibart has become the first anti-TL1A antibody to help patients with ulcerative colitis achieve clinical remission in a phase 3 trial.